Source Data Verification (SDV) is a core activity in clinical trial monitoring, ensuring that data recorded in Case Report Forms (CRFs) match the original source documents. While essential for data integrity and Good Clinical Practice (GCP) compliance, SDV can be resource-intensive and time-consuming if not managed properly. This tutorial explores practical strategies to streamline SDV processes without compromising quality or regulatory compliance.

What Is Source Data Verification?

Source Data Verification is the process by which monitors (typically Clinical Research Associates or CRAs) compare the data entered into the trial database with the source documentation (e.g., patient charts, lab reports, hospital records) to confirm accuracy, completeness, and protocol adherence. As per USFDA and ICH GCP guidelines, SDV is a required part of clinical trial oversight.

Why Is SDV Important?

• Ensures reliability and credibility of trial results
• Detects transcription errors or protocol deviations
• Supports regulatory submissions and audits
• Maintains subject safety and data traceability

Challenges in Traditional SDV Approaches

• High cost due to frequent site visits
• Time-consuming manual verification process
• Discrepancies between paper source and EDC entries
• Overburdened CRAs and site staff

Best Practices for Efficient SDV

1. Adopt a Risk-Based Monitoring (RBM) Approach

Risk-based SDV prioritizes verification based on protocol complexity, site performance, and data criticality. Instead of 100% SDV, focus on:

• Primary and secondary efficacy endpoints
• Informed consent forms
• Serious adverse events (SAEs)
• Eligibility criteria and dosing

This approach aligns with ICH E6(R2) recommendations and optimizes resource allocation.

2. Use eSource and EDC Integration

eSource enables direct data capture at the point of care, reducing transcription and improving SDV efficiency. Integration with EDC platforms allows for real-time verification and audit trails.

Ensure your eSource tools comply with GMP guidelines for electronic data integrity and 21 CFR Part 11 validation.

3. Plan SDV Activities Strategically

Include SDV planning in the Monitoring Plan and Data Management Plan (DMP). Define:

• Percentage and type of data to be verified
• Trigger points for increased or reduced SDV
• Remote vs. on-site SDV capabilities
• CRA tools and templates to use

4. Leverage Remote SDV Where Possible

Remote SDV enables monitors to access electronic medical records (EMRs) or scanned source documents securely. It reduces travel costs and expedites review cycles.

Ensure systems used for remote access are secure, and that consent has been obtained from sites for remote monitoring. This technique became widely adopted during the COVID-19 pandemic and is still supported by Stability Studies and regulatory agencies for decentralized trials.

5. Use SDV Logs and Tracking Tools

Maintain a Source Data Verification Log to track:

• Date and method of SDV
• Sections verified
• Discrepancies noted and resolved
• CRA initials and comments

This ensures transparency and supports audit readiness.

Tools for Managing SDV Efficiently

• EDC platforms with integrated SDV flags (e.g., Medidata Rave, Veeva Vault)
• Monitoring portals (e.g., TrialMaster, Clinion)
• Document sharing tools with audit trails
• Excel-based SDV tracking templates

Training CRAs for Consistent SDV Execution

Train CRAs on protocol requirements, SDV procedures, and system navigation. Provide:

• SDV checklists
• Examples of source-CRF discrepancies
• Mock SDV sessions during SIVs (Site Initiation Visits)
• Access to SOP validation in pharma for reference

Documenting and Reporting SDV Findings

SDV findings should be summarized in:

• Monitoring Visit Reports (MVRs)
• Deviation Logs
• Follow-up Letters to Sites
• Quality Management Review meetings

SDV Metrics for Oversight and Optimization

• % of CRF fields verified
• % of discrepancies found
• Time per SDV cycle per subject
• Cost per verified page

These metrics can guide process improvements and site training efforts.

Conclusion

Managing SDV efficiently requires a combination of technology, planning, and protocol understanding. By adopting risk-based strategies, leveraging eSource, and enabling remote verification, sponsors and CROs can reduce burden while maintaining data quality. Continuous monitoring, proper documentation, and CRA training are essential for successful SDV implementation in both centralized and decentralized trial models.

Source Data Verification (SDV) is a key component of clinical trial monitoring. It ensures that data entered into case report forms (CRFs) or electronic data capture (EDC) systems accurately reflect the source documents maintained at the clinical site. This tutorial provides a step-by-step guide for Clinical Research Associates (CRAs) and site staff to perform SDV efficiently, in alignment with regulatory and sponsor expectations.

What Is Source Data Verification (SDV)?

SDV is the process of comparing data recorded in the trial database to the original source data — such as patient charts, lab reports, or signed informed consent forms. As per USFDA and EMA guidance, SDV is a critical activity that supports the integrity, reliability, and credibility of clinical trial data.

Types of Source Documents in Clinical Trials

• Hospital medical records (paper or electronic)
• Clinic progress notes
• Signed informed consent forms (ICFs)
• Laboratory test reports
• Imaging reports (e.g., CT, MRI)
• Subject diaries and questionnaires
• Investigational product (IP) accountability records

When Is SDV Performed?

SDV typically occurs during Routine Monitoring Visits (RMVs), Interim Monitoring Visits, or Close-out Visits. It is guided by the monitoring plan, protocol-specific requirements, and risk-based monitoring strategies. Sites handling high-risk trials or critical data points (e.g., primary endpoints or safety data) undergo more frequent SDV.

Step-by-Step SDV Process for CRAs

Step 1: Review Pre-Visit SDV List

• Download the SDV checklist or plan from the CTMS
• Focus on subject visits flagged by the sponsor (e.g., first patients, SAE cases)
• Review pending data entry in EDC and missing forms

Step 2: Verify Informed Consent

• Ensure subject signed the latest IRB-approved ICF version
• Check date/time against study procedures (must be signed before any procedure)
• Confirm witness or translator signatures if applicable

Step 3: Compare EDC Entries with Source

• Verify subject demographics, inclusion/exclusion criteria
• Cross-check vital signs, labs, and adverse events
• Ensure IP administration dates match dispensing logs
• Confirm visit dates align with subject calendars and protocol schedule

Step 4: Document Discrepancies

• Flag any discrepancies in SDV notes or CRA worksheets
• Query unresolved differences in EDC and note justification
• Discuss with site staff and request updates or clarifications

Step 5: Sign Off SDV Completion

Once the verification is complete for a visit, the CRA should:

• Mark SDV status as complete in EDC (if system allows)
• Update CTMS visit report with SDV summary
• Note any findings in the Monitoring Visit Report (MVR)

Difference Between SDV and SDR (Source Data Review)

While SDV focuses on the exact data match between CRFs/EDC and source, Source Data Review (SDR) involves a broader assessment of documentation completeness, protocol adherence, and overall data quality. For example, checking whether a lab result was reviewed by the PI is part of SDR, not SDV.

Best Practices for Efficient SDV

• Organize source files by subject and visit
• Highlight sections to be verified using color-coded tabs
• Use digital source documents when permitted, following 21 CFR Part 11
• Maintain SDV logs to track pending or partial verifications
• Train site coordinators in SDV preparation using SOP templates

How Sponsors Use SDV Metrics

Sponsors analyze SDV completion rates, error trends, and CRA visit timelines to monitor trial quality. A sudden rise in discrepancies may prompt closer scrutiny or targeted re-training. Sponsors may also compare SDV rates with quality indicators from Stability Studies or risk-based monitoring platforms.

Regulatory Expectations for SDV

Regulators expect documented evidence of SDV activity. During inspections, agencies like the CDSCO or Health Canada may request:

• Signed CRA SDV checklists
• Monitoring Visit Reports with SDV coverage summaries
• Follow-up documentation of discrepancies

Conclusion

Source Data Verification is a cornerstone of clinical trial quality. By following structured steps and best practices, CRAs and site staff can ensure data consistency, reduce regulatory risk, and build confidence in the trial results. Effective SDV not only improves data reliability but also demonstrates a strong compliance culture, essential for successful trial completion and future audits.

Standardizing Source Data Verification (SDV) is essential for ensuring consistent monitoring across sites and trials. Well-crafted SDV plan templates and SOPs guide Clinical Research Associates (CRAs) in executing and documenting SDV activities in alignment with regulatory expectations. In this tutorial, we’ll walk through the structure, content, and implementation of effective SDV documentation tools.

Why SDV Plans and SOPs Are Important

Without standardized procedures, CRAs may perform SDV inconsistently, leading to audit risks, missed data discrepancies, or non-compliance. Regulators such as USFDA and CDSCO expect sponsors to document how data is verified and to have procedures that ensure subject safety and data integrity.

Components of a Strong SDV Plan Template

An SDV plan is typically part of the overall Monitoring Plan but can also exist as a standalone document. Key components include:

1. Objectives and Scope

• Define what SDV is and its purpose in the context of the specific study
• Clarify whether full or risk-based SDV is applied

2. Roles and Responsibilities

• Outline the responsibilities of CRAs, site staff, and data managers
• Include communication and escalation workflows

3. Data Fields and Frequency

• Specify which fields (e.g., informed consent, AEs, primary endpoints) require 100% SDV
• Set frequency per subject visit (e.g., screening, dosing, follow-up)

4. Documentation and Tracking

• Provide templates for SDV checklists and CRF/EDC audit trails
• Reference tools like CTMS for tracking SDV progress

5. Risk Triggers

• Include escalation protocols if discrepancies or data quality issues arise
• Define site re-training or corrective action procedures

Creating an SDV SOP: What to Include

An SOP should provide operational guidance for CRAs and quality personnel. A recommended structure includes:

Section 1: Purpose

Explain why the SOP exists and how it ensures consistency in SDV execution.

Section 2: Scope

State whether the SOP applies to all studies or only specific types (e.g., pivotal, Phase 3 trials).

Section 3: Definitions

• SDV
• Source Documents
• EDC
• Critical Data

Section 4: Procedure

1. Pre-Visit Planning: Retrieve the SDV plan and subject-specific CRFs
2. Verification: Match data from source documents to the EDC
3. Discrepancy Handling: Record, query, and resolve mismatches
4. Documentation: Complete SDV logs and update monitoring reports

Section 5: Responsibilities

• CRA: Conducts SDV and documents findings
• Site Staff: Provides access to source data and implements corrections
• QA Manager: Reviews SOP adherence during audits

Section 6: References

• EMA GCP Guidelines
• Pharma SOP templates
• Stability Studies practices on source documentation

Using Templates Effectively

Ready-made templates allow for quick customization per protocol. Elements to include:

• Study-specific SDV checklist (screening, baseline, follow-up)
• Source data log
• Subject visit tracker with SDV columns
• Deviation and issue tracking sheet

Best Practices for Maintaining SDV SOPs

• Review SOPs annually or after each trial phase
• Train CRAs using mock SDV visits and SOP walkthroughs
• Maintain version control and change history
• Include SDV audit preparedness steps in SOP annexures

Common Pitfalls to Avoid

• Using outdated templates that don’t reflect current protocol
• Neglecting SDR documentation where applicable
• Failing to align SDV plan with Monitoring Plan or Data Management Plan

Conclusion

Well-defined SDV plan templates and SOPs are cornerstones of high-quality clinical monitoring. They not only improve operational consistency but also demonstrate compliance during audits. For CRAs, QA professionals, and sponsors, investing time in designing practical, risk-based, and regulatory-aligned SDV documentation ensures accuracy, efficiency, and inspection readiness.

During Source Data Verification (SDV), Clinical Research Associates (CRAs) access highly sensitive subject information, including medical records, lab reports, and identifiable data. It is critical that this process complies with privacy regulations such as HIPAA, GDPR, and ICH-GCP. This tutorial outlines the best practices to ensure data privacy and subject confidentiality during SDV activities.

Why Is Data Privacy Important During SDV?

Patient confidentiality is a fundamental ethical and legal requirement in clinical trials. During SDV, if privacy safeguards are not followed, there can be risks of data breaches, regulatory non-compliance, and loss of trial credibility. Authorities like the USFDA and EMA mandate that personal health information (PHI) be accessed and handled securely and only by authorized personnel.

Key Regulations Guiding Confidentiality in SDV

• HIPAA (USA): Protects PHI and governs how it is accessed and disclosed
• GDPR (EU): Requires strict controls on processing personal data
• ICH E6(R2): Highlights the importance of confidentiality in source document access

Best Practices for Protecting Privacy During SDV

1. Limit Access to Authorized Personnel

• Only trained CRAs with site delegation should perform SDV
• Access to source documents must be supervised by site staff
• Log CRA access and time spent on sensitive records

2. Use Secure Locations for SDV

• Conduct SDV in private areas of the site (not patient-care zones)
• Ensure no unauthorized individuals can observe or overhear data

3. Avoid Recording PHI in Monitoring Reports

• Never copy full patient names, initials, or identifiers into visit reports
• Use anonymized subject IDs (e.g., Subject 102-001) in documentation
• Summarize findings without transcribing confidential content

4. Handle Electronic Records with Security

• Do not take photos or screenshots of electronic health records (EHRs)
• Use read-only systems when possible for EDC and CTMS access
• Enable automatic session timeouts and audit trails in electronic systems

5. Implement Redaction Protocols

• Sites should redact non-essential identifiers from printed source docs
• CRAs should report any unredacted data without recording it elsewhere
• Include redaction steps in your SOP for SDV

Handling Source Documents Respectfully

SDV involves reviewing case notes, lab reports, and diagnostic tests. CRAs must:

• View only the documents specified in the monitoring plan
• Return documents promptly after review
• Not remove or scan any patient-related documents from the site

CRA Training on Confidentiality

All CRAs must receive documented training on:

• GCP confidentiality standards
• Site-specific privacy policies
• HIPAA and GDPR requirements (where applicable)

This training should be documented in the CRA’s qualification file and updated periodically, especially when SOPs are revised or data protection laws are updated.

Subject Consent and Privacy Rights

As per ICH-GCP, informed consent documents must clearly state:

• That authorized monitors may access subject data
• That such access will maintain strict confidentiality
• That data will be de-identified in any public reports

Documenting Privacy Measures in the MVR

• “SDV was performed in a private room with access restricted to authorized CRA and site coordinator.”
• “No PHI was recorded in the MVR or removed from the site.”
• “Patient IDs were anonymized in CRF and SDV logs.”

Tools to Support Privacy Compliance

• Site-controlled EHR access terminals
• Secure CTMS with audit logs for SDV tracking
• SDV checklists that exclude PHI fields

Resources such as Stability Studies often provide guidance on managing documentation without breaching subject privacy.

Common Privacy Violations to Avoid

• Writing full names or MRNs in MVRs
• Sending patient data over unsecured email or personal devices
• Leaving source docs unattended at the site
• Using personal storage (e.g., USB drives) to retain trial data

Regulatory Audits and Privacy

Agencies including Health Canada often review how SDV was conducted. Lack of privacy safeguards can result in major audit findings and delays in trial approval or data acceptance.

Conclusion

Ensuring confidentiality during SDV is not just good practice—it’s a legal and ethical necessity. CRAs, sponsors, and site staff must work together to embed privacy protection into SDV workflows, tools, and documentation. Adhering to GCP and regulatory guidance helps maintain participant trust, ensures audit readiness, and upholds the credibility of your clinical trial.

Source Data Verification (SDV) is one of the most crucial aspects of clinical trial monitoring. It ensures that data reported in the Case Report Forms (CRFs) is consistent with the original source records. While CRAs are responsible for executing SDV, site staff play a pivotal role in facilitating accurate, complete, and compliant data entry and documentation. Properly trained site personnel can drastically reduce data discrepancies, protocol deviations, and regulatory non-compliance.

This tutorial provides a comprehensive approach to training site staff for accurate SDV processes. Whether you’re a sponsor, CRO, investigator, or study coordinator, you’ll learn how to prepare your team to support high-quality data monitoring and meet global compliance standards.

Why SDV Training for Site Staff Matters

• Enhances Data Quality: Well-trained staff produce cleaner, more consistent data, reducing CRF discrepancies.
• Reduces Monitoring Time: Fewer queries and less rework during monitoring visits.
• Improves Audit Readiness: Accurate SDV practices demonstrate protocol compliance and traceability.
• Facilitates Regulatory Compliance: Proper source documentation aligns with USFDA and EMA expectations.
• Supports Remote Monitoring: Especially important when using eSource systems and EMRs.

Core Objectives of SDV Training

Site staff should come away from SDV training with the ability to:

• Understand what constitutes source data and source documentation
• Recognize the role of CRAs and how monitoring visits work
• Prepare complete, contemporaneous, and legible source documentation
• Maintain consistency between source data and CRFs
• Respond appropriately to CRA queries and data clarifications
• Securely manage source documents and uphold subject confidentiality

Who Should Receive SDV Training?

Training should include all site personnel directly or indirectly involved in trial documentation and monitoring activities:

• Principal Investigator (PI)
• Sub-Investigators
• Study Coordinators
• Research Nurses
• Pharmacists involved in drug dispensing logs
• Data Entry Operators (DEOs)
• Administrative and regulatory support staff

Recommended Topics to Include in SDV Training

1. Introduction to SDV: What is SDV? Why is it critical?
2. GCP Overview: Responsibilities under ICH-GCP guidelines
3. Types of Source Documents: Paper, EMR, lab reports, IP logs, consent forms
4. CRF and Source Consistency: How to ensure matching data
5. Responding to CRA Queries: Process and timelines
6. Documentation Standards: ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, and Available)
7. Handling Monitoring Visits: Preparation, escorting monitors, and resolving findings
8. Confidentiality and Access Control: Respecting patient data privacy
9. Inspection Readiness: How accurate SDV supports audits and inspections

Training Delivery Formats

Site staff may vary in their learning styles and roles. A blended training strategy is often most effective:

• Onsite Workshops: Led by the CRA or Clinical Trial Manager, these provide hands-on demonstrations.
• Online Modules: Offer flexible and consistent training content for rotating staff.
• Role-Based Sessions: Tailored tracks for investigators, coordinators, nurses, etc.
• Interactive Case Studies: Using sample CRFs and mock discrepancies improves retention.
• Job Aids: Posters, SDV checklists, and SOP reminders around the trial office

Several GMP compliance training vendors and CROs offer standardized SDV training materials aligned with regulatory guidelines.

Best Practices for Site SDV Readiness

• Ensure source documents are updated and available prior to monitor visits
• Pre-log all visit dates, vital signs, labs, and AE notes in the subject files
• Keep copies of consent forms and protocol amendment acknowledgements
• Use a source-CRF checklist to pre-check for discrepancies
• Ensure access to EMRs is granted for CRAs per site SOP
• Train backup staff in case the coordinator is unavailable during monitoring

Common Mistakes to Avoid

• Delaying source documentation until after CRF entry
• Illegible handwriting or incomplete notes
• Untrained staff responding to CRA queries without PI review
• Failure to maintain version-controlled ICF and protocol documentation
• Providing CRAs unrestricted EMR access without subject-level restriction

Monitoring Feedback Loop

Monitoring visits should be seen as learning opportunities. CRAs should provide constructive feedback to improve site practices. Site staff should:

• Attend CRA debriefings after the visit
• Review Monitoring Visit Reports (MVRs) for findings and recommendations
• Document corrective actions for any SDV-related issues
• Update training logs to reflect new learnings or policy changes

Maintaining Training Documentation

For regulatory inspections and sponsor audits, sites must retain SDV training evidence:

• Signed training attendance sheets
• Training materials and modules used
• Competency assessments or quizzes (if applicable)
• Training log with role, date, trainer, and content covered

Supporting Tools and Resources

Sites can utilize:

• Trial-specific SDV checklists
• Stability testing protocols and document templates
• CRF-to-Source crosswalk matrices
• Monitoring SOPs including CRA roles and documentation expectations

Conclusion

Training site staff for accurate Source Data Verification (SDV) is not a one-time event, but an ongoing commitment to quality, compliance, and excellence in clinical research. With well-structured training programs, clear expectations, and continuous feedback, site teams can build confidence in handling source documentation, supporting CRAs, and ensuring data integrity. These practices directly contribute to faster database lock, cleaner submissions, and ultimately safer and more effective clinical interventions.

Source Data Verification (SDV) is a cornerstone of quality assurance in clinical trials. Yet, despite technological advancements and improved monitoring tools, CRAs and site teams continue to encounter frequent SDV errors that can lead to data inconsistencies, protocol deviations, and regulatory non-compliance. Understanding these errors—and how to proactively prevent them—is essential for maintaining the integrity of trial data and ensuring compliance with ICH-GCP and regulatory agency expectations.

This guide provides an in-depth review of the most common SDV mistakes observed during monitoring visits, along with proven methods to prevent them. The goal is to enhance the reliability of your data while reducing rework, delays, and audit risks.

What Are SDV Errors?

SDV errors refer to mismatches or discrepancies between the data entered into the Case Report Forms (CRFs) and the source documentation maintained by the trial site. These may arise due to incorrect transcription, missing data, untimely updates, or lack of understanding of the protocol requirements.

According to Stability Studies, SDV errors are among the top findings during sponsor audits and inspections, emphasizing the importance of proactive prevention.

Top 10 Common SDV Errors

1. Date Mismatches: CRF dates do not align with source documentation.
2. Inconsistent AE/SAE Reporting: Adverse events reported in progress notes but not entered in CRFs.
3. Incorrect Visit Windows: Visit dates fall outside the protocol-defined timeframes.
4. Unverified Inclusion/Exclusion Criteria: Incomplete or unconfirmed eligibility data in the source.
5. Missing Informed Consent Dates: ICFs not dated or signed correctly.
6. Inaccurate Lab Values: Discrepancies in lab results between source and CRF.
7. Unreported Concomitant Medications: Medications listed in source but not in CRF.
8. Incomplete IP Administration Records: IP dose dates/times missing or unclear.
9. Use of Unapproved Abbreviations: Site notes include unrecognized terms leading to interpretation errors.
10. Non-ALCOA+ Documentation: Entries not legible, accurate, or contemporaneous.

Root Causes of SDV Errors

Understanding the root causes helps in addressing systemic issues rather than just correcting individual errors:

• Lack of site staff training on SDV requirements
• Time constraints during busy clinic hours
• Use of multiple unlinked systems (EMR, pharmacy logs, lab systems)
• Delayed entry of source notes
• Failure to maintain a CRF-to-Source reconciliation log
• Ambiguous protocol language regarding documentation

SDV Error Prevention: Best Practices

Below are proactive measures to prevent SDV errors during clinical trials:

1. Train Site Staff Thoroughly

Site teams should understand the role of SDV, documentation standards (ALCOA+), and specific protocol expectations. Consider developing SOPs on SDV documentation practices and maintaining ongoing SOP training in pharma.

2. Use an SDV Preparation Checklist

• ICF availability and completion check
• CRF-source reconciliation tool
• Inclusion/exclusion criteria summary sheet
• Visit window tracking log

3. Pre-Review Source Documents Before CRA Visits

Site staff should ensure source documents are complete, dated, signed, and stored systematically. Pharmacy logs, lab reports, and vital signs should be collated before monitoring.

4. Implement Dual Verification at the Site

Having a second team member verify critical data points (e.g., AE reporting, IP administration) before CRA visits helps minimize oversight.

5. Standardize Documentation Templates

Use pre-approved templates for adverse events, vital signs, concomitant medications, and IP logs to ensure consistent documentation.

6. Adopt Real-Time Data Entry

Delay between patient visits and source entry can result in forgotten details or incomplete entries. Encourage contemporaneous documentation.

7. Establish a Query Resolution SOP

Develop clear processes for resolving CRA queries within specified timelines and assign responsibilities (e.g., PI reviews AE queries, coordinators handle lab discrepancies).

Technology-Enabled Solutions

• eSource Integration: Use platforms that link EMRs with EDCs to reduce transcription errors.
• Audit Trails: Ensure systems record who accessed/edited data.
• Remote SDV Capabilities: Allow monitors to pre-review EMR data securely before onsite visits.
• Dashboards: Visualize outstanding queries, unresolved discrepancies, and visit schedules.

According to GMP guidelines, maintaining robust digital records is increasingly vital to audit success.

Role of CRAs in Preventing SDV Errors

Monitors are not only verifiers but also educators and quality stewards. CRAs should:

• Provide pre-visit and post-visit feedback
• Document site performance trends
• Highlight recurring SDV issues and recommend process changes
• Encourage continuous site training and documentation improvement

Handling SDV Findings and CAPAs

When SDV errors are identified, they must be followed by a Corrective and Preventive Action (CAPA) process:

1. Describe the issue and associated risk
2. Assign responsibility and timelines
3. Implement corrective action (e.g., re-training, document updates)
4. Verify effectiveness during the next monitoring visit

Regulatory Perspective

Agencies like Health Canada expect sponsors and sites to maintain accurate, verified, and retrievable data. Frequent or unresolved SDV errors may trigger inspection findings or lead to data exclusion in regulatory submissions.

Checklist for Error-Free SDV

• All CRF entries match the source exactly
• Protocol visit windows are tracked
• AEs and SAEs are consistently reported
• ICFs are complete and signed pre-procedure
• Lab values, meds, IP, and vitals are reconciled
• CRAs leave no unresolved query behind

Conclusion

Source Data Verification (SDV) errors are not inevitable—they are preventable with the right training, tools, planning, and collaboration. By empowering both CRAs and site staff to recognize red flags, implement robust documentation practices, and leverage supportive technology, sponsors can minimize the risk of SDV-related issues and safeguard the credibility of their clinical data. As the clinical trial landscape evolves, accurate SDV remains a cornerstone of compliance and quality.